📊 PSTV Key Takeaways
Is Plus Therapeutics, Inc.. (PSTV) a Good Investment?
PSTV faces severe financial distress with -$7.1M operating loss on only $1.0M revenue (-10.5% YoY) and -$6.2M operating cash burn. With $3.0M cash against ~$7M annual burn rate, the company has critical liquidity runway of less than 6 months. While gross margin of 40.1% suggests product viability, the company is destroying shareholder value (-58.1% ROE) with no visible profitability trajectory.
Plus Therapeutics, Inc.. Key Strengths (PSTV)
- Gross margin of 40.1% indicates product-level unit economics and pricing power
- Current ratio of 2.27x and quick ratio of 2.25x provide near-term liquidity buffer
- Moderate leverage at 0.32x debt-to-equity limits immediate refinancing pressure
PSTV Stock Risks: Plus Therapeutics, Inc.. Investment Risks
- Critical cash runway: $3.0M cash against $7.1M annual burn rate equals ~5 months survival
- Revenue declining 10.5% YoY despite fundamental need to scale operations
- Massive operating losses with -692.5% operating margin and negative 116.7x interest coverage
- Negative returns destroying equity (-58.1% ROE, -34.9% ROA) with no profitability roadmap
- Limited debt/equity capacity to raise capital given current financial performance
Key Metrics to Watch
- Cash burn rate trend and months of cash runway remaining
- Revenue growth/decline trajectory - stabilization required for survival
- Operating expense levels - ability to reach cash flow breakeven
- Capital raise activity - necessity and terms of additional financing
Plus Therapeutics, Inc.. (PSTV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.27x current ratio provides a solid financial cushion.
PSTV Profit Margin, ROE & Profitability Analysis
PSTV vs Healthcare Sector: How Plus Therapeutics, Inc.. Compares
How Plus Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Plus Therapeutics, Inc.. Stock Overvalued? PSTV Valuation Analysis 2026
Based on fundamental analysis, Plus Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Plus Therapeutics, Inc.. Balance Sheet: PSTV Debt, Cash & Liquidity
PSTV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Plus Therapeutics, Inc..'s revenue has grown significantly by 20% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.34 indicates the company is currently unprofitable.
PSTV Revenue Growth, EPS Growth & YoY Performance
PSTV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.0M | -$6.9M | $-1.05 |
| Q3 2025 | $1.4M | -$2.9M | $-0.04 |
| Q2 2025 | $1.3M | -$2.9M | $-0.01 |
| Q1 2025 | $1.1M | -$3.3M | $-0.75 |
| Q1 2019 | $703.0K | -$3.2M | N/A |
| Q3 2018 | $467.0K | -$2.3M | N/A |
| Q2 2018 | $660.0K | -$3.7M | N/A |
| Q1 2018 | $591.0K | -$4.4M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Plus Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
PSTV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Plus Therapeutics, Inc.. (CIK: 0001095981)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PSTV
What is the AI rating for PSTV?
Plus Therapeutics, Inc.. (PSTV) has an AI grade of D with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PSTV's key strengths?
Claude: Gross margin of 40.1% indicates product-level unit economics and pricing power. Current ratio of 2.27x and quick ratio of 2.25x provide near-term liquidity buffer.
What are the risks of investing in PSTV?
Claude: Critical cash runway: $3.0M cash against $7.1M annual burn rate equals ~5 months survival. Revenue declining 10.5% YoY despite fundamental need to scale operations.
What is PSTV's revenue and growth?
Plus Therapeutics, Inc.. reported revenue of $1.0M.
Does PSTV pay dividends?
Plus Therapeutics, Inc.. does not currently pay dividends.
Where can I find PSTV SEC filings?
Official SEC filings for Plus Therapeutics, Inc.. (CIK: 0001095981) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PSTV's EPS?
Plus Therapeutics, Inc.. has a diluted EPS of $-1.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PSTV's fundamental grade?
Based on our AI fundamental analysis in May 2026, Plus Therapeutics, Inc.. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PSTV stock overvalued or undervalued?
Valuation metrics for PSTV: ROE of -58.1% (sector avg: 15%), net margin of -675.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PSTV's AI grade for 2026?
Our dual AI analysis gives Plus Therapeutics, Inc.. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PSTV's free cash flow?
Plus Therapeutics, Inc..'s operating cash flow is $-6.2M, with capital expenditures of $818.0K. FCF margin is -686.4%.
How does PSTV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -675.7% (avg: 12%), ROE -58.1% (avg: 15%), current ratio 2.27 (avg: 2).